Targeted delivery of doxorubicin and vincristine to lymph cancer: evaluation of novel nanostructured lipid carriers in vitro and in vivo

Figures & data

Table 1. NLCs characterization.

Characters	DOX/VCR NLCs	DOX NLCs	VCR NLCs	Blank NLCs
Size (nm)	95.8 ± 2.1	96.2 ± 2.3	94.9 ± 2.6	94.1 ± 1.7
Potential (mV)	+21.3 ± 2.8	+16.9 ± 1.9	+27.1 ± 2.3	+20.9 ± 1.6
EEDOX (%)	87.9 ± 2.4	88.3 ± 2.7	–	–
EEVCR (%)	83.3 ± 2.1	–	85.8 ± 1.9	–

Figure 1. Accumulated release of DOX from DOX/VCR NLCs, and DOX NLCs.

Figure 2. Accumulated release of VCR from DOX/VCR NLCs, and VCR NLCs.

Table 2. DOX to VCR ratio determination in DOX/VCR NLCs.

DOX to VCR ratios (w/w)	IC50 of DOX (μg/mL)	IC50 of VCR (μg/mL)
5/1	2.15	0.43
2/1	1.92	0.96
1/1	0.26	0.26
1/2	0.85	1.71
1/5	0.38	1.91

Table 3. DOX to VCR ratio determination in DOX/VCR NLCs.

Formulations	IC50 of DOX (μg/mL)	IC50 of VCR (μg/mL)
DOX solution	7.51	–
VCR solution	–	9.82
DOX NLCs	2.63	–
VCR NLCs	–	3.31
DOX/VCR NLCs	0.26	0.26

Figure 3. Tumor volume changes after treatment with different formulations in mice bearing lymph cancer xenograft.

Figure 4. Body weight changes after treatment with different formulations in mice bearing lymph cancer xenograft.